Wednesday, September 4, 2013

Study Shows Joint Symptoms In Postmenopausal Women Not Reduced By Calcium Plus Vitamin D Supplementation

Dr. Enrique Jacome
A team of investigators systematically analyzed the effect of calcium and vitamin D supplementation on joint symptoms in a rigorous and controlled study of postmenopausal women. They found that supplementation did not reduce the severity of joint symptoms reported by the participants. Their results are published in the Journal of the Academy of Nutrition and Dietetics.

The influence of low calcium and vitamin D deficiency on joint symptoms has been studied with mixed results. Only some observational studies have associated vitamin D with knee osteoarthritis and results from full-scale randomized trials have been sparse. "In the current study, we addressed for the first time in a full-scale, randomized clinical trial setting, the clinically relevant question of whether postmenopausal women using calcium and vitamin D supplements in currently recommended dosage would experience any favorable effect on joint pain or swelling, common symptoms in postmenopausal women," says lead investigator Rowan T. Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Torrance, California.

Using data from the Women's Health Initiative (WHI) calcium plus vitamin D supplementation trial, researchers identified a subgroup of 1,911 postmenopausal women for the current study, who had been randomized to receive calcium carbonate with vitamin D3 daily or placebo and had undergone serial joint symptom assessment. Responses to a questionnaire provided qualitative information on joint pain and joint swelling before entry and two years after randomization.

Between the daily supplement use and placebo groups, joint pain and swelling at baseline entry was comparable, at more than 70 percent. After two years, analysis revealed no statistically significant difference for the frequency or severity of joint pain or swelling.

The research team also evaluated data to determine the potential for interaction with age, BMI(body mass index), physical activity, non-protocol calcium and vitamin D supplement use, race/ethnicity, and hormone therapy. Investigators found no interaction with age, BMI, race/ethnicity, or physical activity. No significant interaction was evident with non-protocol vitamin D supplement use at entry. However, participants using non-protocol calcium supplements at entry reported less joint pain compared with those in the placebo group. The influence of calcium and vitamin D supplementation individually on joint symptoms was not determined because both were provided combined in a single pill in this trial.
Dr. Chlebowski concludes, "Joint symptoms are relatively common in postmenopausal women. 

However, daily supplementation with 1,000 mg of calcium carbonate and 400 IU of vitamin D3 in a randomized, placebo-controlled clinical trial setting did not reduce the self-reported frequency or severity of joint symptoms."

Dr. Chlebowski and his team add that these findings do not speak against current recommendations for vitamin D intakes for bone health and fracture risk reduction. 

Saturday, August 24, 2013

Study Shows That Exercise Is Good For Women, But It Won't Cut Hot Flashes

Dr. Enrique Jacome
Exercise has proven health benefits, but easing hot flashes isn't one of them. After participating in a 12-week aerobic exercise program, sedentary women with frequent hot flashes had no fewer or less bothersome hot flashes than a control group. This randomized, controlled study from the MsFLASH Research Network was published in Menopause, the journal of The North American Menopause Society.

The 248 women in the trial were either approaching menopause or were postmenopausal; 142 of them continued to go about their usual activities, and 106 participated in aerobic exercise training three times a week for 12 weeks at a fitness center. All the women kept daily diaries on their hot flashes and night sweats and on how well they slept and also completed questionnaires about insomnia, depression, and anxiety.

Although exercise had small positive effects on sleep quality, insomnia, and depression, it had no significant effect on hot flashes for the women overall. Race and initial fitness did make some difference, however. White women in the exercise program did show improvement in their hot flashes compared with white women who maintained their usual activity level, but there was no similar difference among African-American women. Also, women who were more fit to begin with had greater improvement in their hot flashes with exercise.

The study helps to settle a debate about the effect of exercise on hot flashes. Previous studies have been inconsistent, but this study corroborates a recent Cochrane review on the topic, which concluded that there was no evidence to support the use of exercise as an effective treatment for hot flashes and night sweats.

"Midlife women cannot expect exercise to relieve [hot flashes and night sweats] but may reasonably expect it to improve how they feel and their overall health," said the investigators.

Tuesday, August 20, 2013

Study Shows That Estrogen May Influence Location Of Women's Fat

Dr. Enrique Jacome
Ever wondered why some women, but not all, have the "pear" shape considered by many to be desirable? Researchers might have found some answers to the mystery, after discovering that estrogen, one of the sex hormones, affects where fat is stored in a woman's body.

The study was conducted by researchers from East Carolina University and published in the American Journal of Physiology: Endocrinology and Metabolism. It involved 17 premenopausal women ages of 18 and 44 who were overweight or obese.

Researchers  asked the women to provide:
  • Weight
  • Height
  • Fat percentage
  • Lean body mass
  • VO2 max (a measure of physical fitness).
They then analyzed how estrogen affects fat accumulation in particular areas of the body.
This was done by slowly infusing estrogen into the buttocks and belly of the women overnight. The women were then given drugs that encouraged the burning of fat in the body (lipolysis). They were also asked to exercise at a level similar to a standard exercise session, both with and without the lipolysis drugs.

Fat breakdown was measured using microdialysis - a sampling technique that looks for the amount of glycerol left behind after the breakdown of fat for eventual energy production.

The researchers found that the effect of estrogen on fat deposits was dependent on the deposits' particular location and how the fat is burned.

Results of the study revealed that estrogen halted fat breakdown in the abdomen area when the hormone was infused alongside a lipolysis drug called isoproterenol. However, it did not have the same effect in the buttocks.

The researchers add that after a second drug was infused in the abdomen along with the first, no further fat was broken down.

But when both of the fat-mobilizing drugs were infused together alongside exercise, and when the participants exercised without the drugs, fat breakdown in the abdomen increased, although less in the buttocks.

The study authors say: "Our results indicate that the influence of E2 (estrogen) is dependent on the adipose tissue (loose connecting tissue) depot of interest as well as the specific regulatory mechanism targeted.

The authors add: 
"The importance of understanding estrogen action in adipose tissue is underscored by the fact that adipose tissue is an estrogen-producing organ, particularly in postmenopausal women, where adipose tissue is the major site of estrogen production."

The scientists say their findings could potentially lead to an understanding of why post-menopausal women are more likely to accumulate fat around the abdomen area.

When it comes to pre-menopausal women, the researchers say that the relationship between estrogen and the breakdown of fat is what may help maintain a woman's "pear" shape - more fat around the middle area of the body.

They conclude that further research is needed to determine the mechanisms as to why and how the effects of estrogen vary.

Saturday, August 10, 2013

Recognizing Menopausal Symptoms Is The First Step

Dr. Enrique Jacome
When I ask patients to give me a definition of menopause, I receive a variety of answers that consist of “When you get hot flashes” to “Not having a period for over a year”.  Many women go under diagnosed because of the failure of physicians to apply a scientific method for diagnosis. 

Scientifically, a diagnosis is when the level of follicle stimulation hormone (FSH) reaches a level greater than 23 miu/ml, whether she is menstruating or not. Peri-menopause typically begins when a woman is in her 40’s and can average 4 to 8 years.  Menopause occurs roughly in women their early 50’s. Every year it is estimated that 1.3 million women are expected to reach menopause.

I will take you through a series of symptoms that a woman should look for and what should she do next.  NO woman should ever have to suffer through any symptom(s) nor feel less than a woman.  Menopause is a natural part of the aging process.  Not all symptoms will show in all women.  Please use this as a guide only.
During the menopausal transition women may experience sexual dysfunction as well as depressive symptoms.  Due to the loss of estrogen, one’s symptoms can also consist of:
  • Hot flashes
  • Severe sweating – can happen both day and night
  • Insomnia
  • Vaginal dryness
  • Vaginal discomfort
  • Irritability
  • Loss of memory or fuzzy thinking
  • Cold sweats
  • Irregular periods
  • Anxiety
  • Mood swings
  • Headaches
  • Sadness
When a woman comes to me with symptoms, as previously stated, I take the time to listen to what each individual patient is telling me, never discounting any of their feelings or symptoms.  My immediate instinct as a Doctor is to help her improve her symptoms and get her on the right track to feeling like a woman again.  My first recommendation is that they have a simple blood test that will measure their pituitary hormone Follicle Stimulating Hormone (FSH) level. Depending upon the blood work I get back from their testing’s, my suggested and most successful form of hormone replacement would be via the Pellet Hormone Delivery System (PHDS). Women who have their hormones replaced via PHDS allows the body to recreate a continuous flow of hormones that the ovaries normally and previously produced within their bodies.  This method of delivery is more important than any other type of replacement therapy as it is surgically inserted and allows the body to control the release of the hormones over time.  Nothing in an oral, patch or cream can reproduce the normal hormone correction that is needed.
Always remember to go with your instinct regarding how you are feeling and if you are displaying some of the symptoms above, as each woman knows best how they should feel and seek the advice of a doctor.  Don’t ever give in or give up to the ugly face of menopause.
Remember to put your fears away, as life during and after menopause can be quite enjoyable!

Thursday, August 8, 2013

Urinary Infection During Menopause Treated With Estrogen In Mouse Study

Dr. Enrique Jacome
Estrogen levels drop dramatically in menopause, a time when the risk of urinary tract infections increases significantly. 

Researchers at Washington University School of Medicine in St. Louis have found new evidence in mice that the two phenomena are connected by more than just timing. If further research confirms these links, boosting estrogen levels may get a second look as an approach for reducing urinary infections in menopausal women. 

"Scientists tested estrogen as a treatment for post-menopausal women with urinary tract infections in the 1990s, but the results were either ambiguous or negative," says senior author Indira Mysorekar, PhD, assistant professor of obstetrics and gynecology and of pathology and immunology. "With the mouse model of menopause that we've created, we can more completely understand how estrogen levels affect infection susceptibility, bladder health and the inflammatory response to infection. That should point the way to better treatment strategies." 

The findings appear online in Infection and Immunity. 

Urinary infections are a significant cause of illness in many women throughout their lives and are particularly prevalent after menopause. The bacteria that cause these infections can spread to the kidney and bloodstream, with the potential for serious complications. 

To simulate menopause in mice, scientists surgically remove their ovaries. Like menopausal women, the mice no longer make estrogen. 

To rule out the possibility that the stress of surgery affects the risk of urinary tract infections, the researchers conducted the same surgery in other mice but put the ovaries back in, maintaining their ability to make estrogen. 

When researchers gave both groups of mice urinary tract infections, the menopausal mice had higher levels of infectious bacteria in their urine. Most of the bacteria came from barrier cells, which line the interior of the bladder. These cells are the first to be infected by the bacteria. 

"When the barrier cells are lost, they need to be replaced immediately," Mysorekar says. "In the menopausal mice, we found that this replacement process was stopping short of completion. That left cells under barrier cells exposed, and they are much more vulnerable to infection." 

The menopausal mice had more bacterial reservoirs, which are pockets of infection that may provide a place for the bacteria to hide during antibiotic treatment. After treatment stops, the reservoirs can reseed the infection. 

In earlier research, Mysorekar had identified an important regulator of the barrier cell repair process. In the new study, she showed that low estrogen levels disable this regulator. 

The bladders of the menopausal mice also had higher levels of immune inflammatory compounds known as cytokines. 

"The cytokines caused inflammation that left the bladder in bad shape," Mysorekar says. "It's possible that damage caused by inflammation increases the bacteria's ability to break into bladder tissue and create reservoirs of infection." 

In the control mice, which had normal estrogen levels, cytokine levels and inflammatory damage were both significantly lower. When researchers gave the menopausal mice estrogen, their cytokine levels and inflammatory damage also decreased significantly, as did reservoirs of infectious bacteria. 

Mysorekar notes that earlier clinical trials of estrogen's usefulness against urinary infection evaluated the treatment's success by tracking levels of bacteria in the urine. The researchers say their new results suggest that bacteria levels alone may not provide a complete picture of estrogen's effectiveness against the infections. 

"If we can find ways to look at other aspects of the infectious process in humans, we may find that estrogen is more helpful than we previously realized," Mysorekar says. "We need to look for other indicators, such as cytokines in the urine, to more fully assess estrogen's potential role in treatment." 


www.vivenaturalhormones.com

Saturday, July 27, 2013

According To A Recent Animal Study, Estrogen Enables Females To Respond Better To Stress

Dr. Enrique Jacome
The idea that females are more resilient than males in responding to stress is a popular view, and now University at Buffalo researchers have found a scientific explanation. The paper describing their study is published online in the high-impact journal, Molecular Psychiatry.

"We have examined the molecular mechanism underlying gender-specific effects of stress," says senior author Zhen Yan, PhD, a professor in the Department of Physiology and Biophysics in the UB School of Medicine and Biomedical Sciences. "Previous studies have found that females are more resilient to chronic stress and now our research has found the reason why."

The research shows that in rats exposed to repeated episodes of stress, females respond better than males because of the protective effect of estrogen. In the UB study, young female rats exposed to one week of periodic physical restraint stress showed no impairment in their ability to remember and recognize objects they had previously been shown. In contrast, young males exposed to the same stress were impaired in their short-term memory.

An impairment in the ability to correctly remember a familiar object signifies some disturbance in the signaling ability of the glutamate receptor in the prefrontal cortex, the brain region that controls working memory, attention, decision-making, emotion and other high-level "executive" processes.

Last year, Yan and UB colleagues published in Neuron a paper showing that repeated stress results in loss of the glutamate receptor in the prefrontal cortex of young males.

The current paper shows that the glutamate receptor in the prefrontal cortex of stressed females is intact. The findings provide more support for a growing body of research demonstrating that the glutamate receptor is the molecular target of stress, which mediates the stress response. The stressors used in the experiments mimic challenging and stressful, but not dangerous, experiences that humans face, such as those causing frustration and feelings of being under pressure, Yan says.

By manipulating the amount of estrogen produced in the brain, the UB researchers were able to make the males respond to stress more like females and the females respond more like males.

"When estrogen signaling in the brains of females was blocked, stress exhibited detrimental effects on them," explains Yan. "When estrogen signaling was activated in males, the detrimental effects of stress were blocked.

"We still found the protective effect of estrogen in female rats whose ovaries were removed," says Yan. "It suggests that it might be estrogen produced in the brain that protects against the detrimental effects of stress." In the current study, Yan and her colleagues found that the enzyme aromatase, which produces estradiol, an estrogen hormone, in the brain, is responsible for female stress resilience. They found that aromatase levels are significantly higher in the prefrontal cortex of female rats.

"If we could find compounds similar to estrogen that could be administered without causing hormonal side effects, they could prove to be a very effective treatment for stress-related problems in males," she says. She notes that while stress itself is not a psychiatric disorder, it can be a trigger for the development of psychiatric disorders in vulnerable individuals.

Tuesday, July 23, 2013

Study Shows Estrogen-Only Therapy After Hysterectomy May Be A Lifesaver

Dr. Enrique Jacome
The widespread rejection of estrogen therapy after the 2002 Women's Health Initiative (WHI) study has most likely led to almost 50,000 unnecessary deaths over the last 10 years among women aged 50 to 69 who have had a hysterectomy, Yale School of Medicine researchers reveal in a study published in the American Journal of Public Health.

Led by Philip Sarrel, M.D., emeritus professor in the Departments of Obstetrics, Gynecology & Reproductive Sciences, and Psychiatry, the researchers analyzed United States census data, hysterectomy rates, and estimates of decline in hormone use in women aged 50 to 59 between 2002 and 2011.

Before 2002, it was standard practice for doctors to recommend estrogen therapy for this slice of the population, and more than 90% of these women used it to treat symptoms such as hot flashes, and to prevent osteoporosis and other diseases related to menopausal hormone deficiency. Today, about 10% of these women use estrogen.

This sharp decline in estrogen usage was linked to results from one part of the large, federally funded WHI study in 2002. Women and their doctors became frightened of the dangers of post-menopausal hormones. But according to Sarrel and his colleagues, this was a report about women with a uterus, who took pills that combined estrogen and a progestin. Women who have a uterus must take a second hormone (a progestin) to avoid a risk of uterine cancer. But these results did not apply to women with no uterus who use estrogen-only therapy.

"Sadly, the media, women, and health care providers did not appreciate the difference between the two kinds of hormone therapy," Sarrel said. "As a result, the use of all forms of FDA-approved menopausal hormone therapy declined precipitously."

Sarrel added that for the women taking combined hormone therapy (at least the particular drug, Prempro, used in the WHI study), it was probably a good decision to avoid it because the WHI study showed a significant increase in breast cancer, heart disease, stroke, and blood clots in women who used this drug compared to placebo. However, for the women taking estrogen-only therapy, avoiding treatment does not appear to have been a good decision.

Results from the second part of the WHI study, which followed women who had no uterus and who took either estrogen-only or placebo, were very different. A series of papers published by the WHI between 2004 and 2012 showed that estrogen-only therapy had mostly positive health outcomes. For example, in 2011 and 2012 the WHI reported that women who received estrogen compared to those who received placebo had fewer deaths each year for 10 years and were less likely to develop breast cancer and heart disease. For each of the 10 years the death rate among those not taking estrogen was 13 more per 10,000. Most of these women died from heart disease while breast cancer accounted for almost all the other deaths.

"Estrogen avoidance has resulted in a real cost in women's lives every year for the last 10 years - and the deaths continue," said Sarrel. "We hope this article will stir an overdue debate and raise consciousness about the health benefits of estrogen-only therapy for women in their 50s with no uterus."

www.vivenaturalhormones.com